To the Editor,
The debate on what tube is most accurate for glucose estimation has been ongoing for several years. Fasting plasma glucose (FPG) estimation accuracy is central in the diagnosis of diabetes [1] . Having a tube with anticoagulant that preserves glucose concentration immediately is pivotal for correct classifications. The guideline recommends the sample tube be immediately placed in an ice-slurry and the plasma be separated from cells within 30 min [2] . The guideline is not only impractical, but it is also difficult to enforce for compliance if the collection is off-site. Laboratories do not always receive these or other samples in timely manner, within 10-15 min to centrifuge and analyse samples.
The transport/storage temperature can be variable, analytical equipment may not be available due to technical issues, and even if all the above criteria are optimised, cellular activity continues to alter the glucose concentration. We have looked at almost all the alternatives on tube appropriateness and we did not find a definite solution [3] . Terumo had the Venosafe Glycaemia tube, which was reported to increase the number of patients with abnormal FPG >7.0 mmol/L from 17.8% to 23.3% [4] . This tube is no longer on the market. What is also of concern is the actual number of false low-glucose results in samples routinely collected in standard serum and lithium heparin tubes as part of chemistry profiles where pre-analytical factors vary and glucose consumption would be significant.
Greiner has released the new FC Mix Glucose tube with the dry anticoagulants combination. We undertook a study to evaluate the stability of glucose in this tube. The study was divided in two parts. The first part involved recruiting participants with consent, which was approved by the Princess Alexandra Hospital Ethics (Greiner Bio-one, Kremsmuster, Austria) by a phlebotomist without any specific order of draw. The tubes were centrifuged within 10 min of collection at 3000 g for 10 min at 20 °C. There were 41 participants recruited, 35 normal and 6 with diabetes. The reason being the most significant effect on glucose is at around the diagnostically important cut-off values [5] . The lithium heparin plasma was used as the reference sample [2] , but these tubes were not placed in an ice slurry; intead, they were centrifuged within 10 min of collection then analysed immediately post-centrifugation along with the FC Mix and NaF tube for each participant. The centrifuged NaF/K oxalate and FC Mix tubes were stored at 23 °C (room temperature; RT) and reanalysed at 2-and 4-h intervals to determine if the glucose concentration would change.
The second part was the stability study. In our organisation, samples can be exposed to higher temperatures in the pre-analytical phase; hence, it is important to test the inhibitory ability of the FC Mix tube to preserve glucose concentration at various temperatures. Samples were collected from two volunteers in the NaF/K oxalate and the FC Mix tubes. A set of 10 of each tube was collected, pooled and aliquoted into vials for incubation over 0.5, 1.0, 2.0 and 4.0 h at 23 °C (RT), 2-8 °C and 37 °C. The zero time aliquot for each tube was immediately centrifuged (within 10 min of collection) and the plasma was aliquoted into clean tubes. The other aliquots were incubated uncentrifuged for the required times, then centrifuged, and the plasma was aliquoted into clean tubes. The plasma samples were then all analysed in triplicate at the same time on the same analyser.
The analysis was performed on a Beckman DxC800 general chemistry analyser (glucose oxidase method; Beckman Coulter, Brea, CA, USA). The glucose method coefficient of variation (CV) for the two internal controls were QCL1 mean 4.49 mmol/L, CV 2.26% and QCL2 mean 15.43 mmol/L CV 1.22%. The CV of QCL1 was used to determine if results would fall outside the analytical error (>2.3%), which would indicate that the change is due to glycolysis.
Statistical analysis was performed using the Microsoft Excel and Analyse-It statistical add-on for Microsoft Excel (Analyse-It, Leeds, UK). The patient comparisons were assessed by Passing Bablok regression correlation.
For the sample comparison study, the participants' glucose range was 4.29-12.76 mmol/L. The correlation equations, mean glucose concentration and the mean differences from the lithium heparin tube for the FC Mix and NaF/K oxalate tubes are shown in Table 1 . The results clearly show the FC Mix correlates much better than the NaF/K oxalates with lithium heparin plasma results. The prolonged storage (2 and 4 h) of the centrifuged tubes showed that both tubes maintained the change in glucose concentration to less than the technically allowable limit, preventing any analytically significant glucose decrease at RT. However, there is a slight decrease with the NaF/K oxalate samples.
The stability study results are shown in Table 2 . For the FC Mix, the change in glucose concentration at different storage times and temperatures was less than the technical limit (<2.3%), and no analytically significant effect was observed. However, with the NaF/K oxalate tube, glycolysis was slowest at the lowest storage temperature, 2-8 °C, whereas it was fastest at 37 °C. Both at RT and 37 °C storage, the glycolysis peaks and stops at 2 h with around 7.5% decrease. The samples stored at 2-8 °C up to 1 h showed a decrease, but it was less than analytical limit.
One notable observation was the plasma in the FC mix tube had, in about ~15% of samples, a darker brown appearance, giving a higher haemolytic index (HI) (mean HI: lithium heparin plasma, 0.05; NaF/K oxalate, 0.93; FC [4] . In this study, the differences between the means were minimal. However, this shift increased with delayed processing of samples collected in the NaF/K oxalate tubes, but not to the level observed by Pasqualetti et al. Laboratories continuing to use the NaF/K oxalate tube should store tubes at 2-8 °C to minimise glucose consumption and improve accuracy in glucose determination. However, these samples should be centrifuged at least within that hour or immediately and continued to be stored at 2-8 °C until analysed if the plasma cannot be separated.
The FC Mix tube has been shown to meet the need for preventing immediate glucose consumption by cells, eliminating false decrease in glucose concentrations. In turn, this will allow patient diagnosis and classifications to be accurately determined at all times.
